Psoriasis is a systemic inflammatory disorder associated with many other chronic and progressive diseases. Ocular comorbidity has been reported in 10-15% of patients with plaque psoriasis, but the real incidence is still underestimated. This paper reports successful treatment with secukinumab of a patient with plaque psoriasis and dry eye syndrome. Secukinumab treatment was rapidly effective on skin psoriasis and this result was in agreement with observations reported in the literature. Interestingly, both the skin condition and the ocular disease improved after treatment. Our experience suggests that this drug should be used in patients with plaque psoriasis and ophthalmologic manifestations.

Secukinumab for plaque psoriasis with ocular comorbidity: a clinical experience

Cannavò, Serafinella P
Primo
;
Postorino, Elisa;Aragona, Emanuela;Bartolotta, Annunziata;Papaianni, Valeria;Guarneri, Claudio
Ultimo
2018-01-01

Abstract

Psoriasis is a systemic inflammatory disorder associated with many other chronic and progressive diseases. Ocular comorbidity has been reported in 10-15% of patients with plaque psoriasis, but the real incidence is still underestimated. This paper reports successful treatment with secukinumab of a patient with plaque psoriasis and dry eye syndrome. Secukinumab treatment was rapidly effective on skin psoriasis and this result was in agreement with observations reported in the literature. Interestingly, both the skin condition and the ocular disease improved after treatment. Our experience suggests that this drug should be used in patients with plaque psoriasis and ophthalmologic manifestations.
File in questo prodotto:
File Dimensione Formato  
Secukinumab for plaque psoriasis with ocular comorbidity.pdf

solo gestori archivio

Tipologia: Versione Editoriale (PDF)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 658.74 kB
Formato Adobe PDF
658.74 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
3131118.pdf

solo gestori archivio

Tipologia: Versione Editoriale (PDF)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 2.97 MB
Formato Adobe PDF
2.97 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3131118
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact